Zimmer Biomet designs, manufactures, and sells orthopedic implants and related surgical products, primarily for joint replacement surgery. Knees and hips are the two core franchises: key products include the Persona knee system, the Oxford Partial Cementless Knee, and a range of total hip systems, with the ROSA robotic system used across both procedures. Zimmer Biomet is building a third leg through its S.E.T. category (sports medicine, extremities, and trauma), which expanded significantly with the 2025 acquisition of Paragon 28, a foot and ankle specialist. Zimmer Biomet sells primarily through a direct salesforce and independent agents in the U.S., and through distributors internationally. About 85% of U.S. sales are consignment-based, meaning Zimmer Biomet stocks inventory at hospitals and ASCs and recognizes revenue only when a device is implanted. Revenue is driven by procedure volumes, product mix, and the installed base of ROSA robotic systems, which pull through implant sales as surgeons default to Zimmer Biomet products once a ROSA is in place. Premium cementless implants carry higher average selling prices than cemented alternatives. Zimmer Biomet is in the middle of converting its U.S. salesforce from independent agents to dedicated employees, a transition expected to complete by end of 2027. Recent acquisitions also include OrthoGrid, an AI-guided hip surgery system, and Monogram Technologies, whose autonomous robotic platform is targeted for a 2027 commercial launch.